Research Summary

My work focuses on the prevention and treatment of HIV infection.

I have been involved in studies of HIV prevention (specifically, truvada for PrEP) for over 12 years. I was the statistician for the iPrEx trial -- the first trial to report the efficacy of oral PrEP and worked on the drugs approval by the FDA. My current work involves studies of the global scale-up of PrEP, innovative designs/statistical analyses of new PrEP agents, and pharmacologic markers of PrEP exposure.

I also collaborate on studies on the outcomes of HIV treatment in resource limited settings. In these settings many patients are absent from clinics. This data requires handling several statistical issues including clustering, competing risk/multiple outcomes, time-dependent covariates and informative censoring. My colleagues and I have pioneered sampling based approaches to losses to follow-up which have given rigorous information about treatment outcomes.

I also collaborate for groups in neurology, pediatrics, LGBT health and nephrology and teach in my department's MCR and Ph.D. program.

Research Funding

  • September 24, 2018 - August 31, 2022 - Statistical methods for clinical trials of novel PrEP agents, Principal Investigator. Sponsor: NIH/NIAIDS, Sponsor Award ID: R01AI143357
  • January 10, 2016 - December 31, 2017 - Comparison of Pharmacologic Markers of Exposure to HIV Pre-Exposure Prophylaxis, Principal Investigator. Sponsor: NIH, Sponsor Award ID: R03AI122908
  • June 19, 2015 - May 31, 2017 - Chemoprophylaxis for HIV Prevention: Analysis of Bone and Metabolic Effects, Principal Investigator. Sponsor: NIH, Sponsor Award ID: R03AI120819
  • April 1, 2001 - March 31, 2006 - FAILURE TIME METHODS FOR FAMILY DISEASE STUDIES, Principal Investigator. Sponsor: NIH, Sponsor Award ID: R01HL065411


University of California, Berkeley, CA, BA, 1988, Statistics
University of Washington, Seattle, WA, PhD, 1993, Biostatistics
Harvard University, Boston, MA, Fellowship, 1995, Biostatistics

Honors & Awards

  • 1988
    W.W. Stout Fellowship, Graduate School, University of Washington
  • 1988 - 1990
    Graduate Fellowship Award, Graduate School, University of Washington
  • 1990 - 1993
    National Research Service Award, National Heart, Lung and Blood Institute
  • 1993
    School of Public Health Outstanding Student Citation for Biostatistics, Univ. of Washington
  • 2007
    TICR Award for Excellence in Teaching

Selected Publications

  1. Sevelius JM, Glidden DV, Deutsch M, Welborn L, Contreras A, Salinas A, Venegas L, Grant RM. Uptake, Retention, and Adherence to Pre-exposure Prophylaxis (PrEP) in TRIUMPH: A Peer-Led PrEP Demonstration Project for Transgender Communities in Oakland and Sacramento, California. J Acquir Immune Defic Syndr. 2021 Dec 15; 88(S1):S27-S38.  View on PubMed
  2. Spinelli MA, Peluso MJ, Lynch KL, Yun C, Glidden DV, Henrich TJ, Deeks SG, Gandhi M. Differences in Post-mRNA Vaccination SARS-CoV-2 IgG Concentrations and Surrogate Virus Neutralization Test Response by HIV Status and Type of Vaccine: a Matched Case-Control Observational Study. Clin Infect Dis. 2021 Dec 05.  View on PubMed
  3. Spinelli MA, Brown LB, Glidden DV, Hunter K, Martin-Tuite P, Zheng J, Sera C, Havlir D, Buchbinder SP, Gandhi M. SARS-CoV-2 incidence, testing rates, and severe COVID-19 outcomes among people with and without HIV. AIDS. 2021 12 01; 35(15):2545-2547.  View on PubMed
  4. Sikazwe I, Eshun-Wilson I, Sikombe K, Beres LK, Somwe P, Mody A, Simbeza S, Bukankala C, Glidden DV, Mulenga LB, Padian N, Ehrenkranz P, Bolton-Moore C, Holmes CB, Geng EH. Patient-reported Reasons for Stopping Care or Switching Clinics in Zambia: A Multisite, Regionally Representative Estimate Using a Multistage Sampling-based Approach in Zambia. Clin Infect Dis. 2021 Oct 05; 73(7):e2294-e2302.  View on PubMed
  5. Grant RM, Pellegrini M, Defechereux PA, Anderson PL, Yu M, Glidden DV, O'Neal J, Yager J, Bhasin S, Sevelius J, Deutsch MB. Sex Hormone Therapy and Tenofovir Diphosphate Concentration in Dried Blood Spots: Primary Results of the Interactions Between Antiretrovirals And Transgender Hormones Study. Clin Infect Dis. 2021 Oct 05; 73(7):e2117-e2123.  View on PubMed
  6. Peluso MJ, Lu S, Tang AF, Durstenfeld MS, Ho HE, Goldberg SA, Forman CA, Munter SE, Hoh R, Tai V, Chenna A, Yee BC, Winslow JW, Petropoulos CJ, Greenhouse B, Hunt PW, Hsue PY, Martin JN, Daniel Kelly J, Glidden DV, Deeks SG, Henrich TJ. Markers of Immune Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J Infect Dis. 2021 Sep 27.  View on PubMed
  7. Johnson KA, Okochi H, Glidden DV, Gandhi M, Spinelli M. Brief Report: No Difference in Urine Tenofovir Levels in Patients Living With HIV on Unboosted Versus Dose-Adjusted Boosted Tenofovir Alafenamide. J Acquir Immune Defic Syndr. 2021 Sep 01; 88(1):57-60.  View on PubMed
  8. Maheshwari JA, Kolaitis NA, Anderson MR, Benvenuto L, Gao Y, Katz PP, Greenland J, Wolters PJ, Covinsky K, Hays SR, Kukreja J, Calabrese DR, Venado A, Shah RJ, Leard LE, Trinh B, Huang CY, Glidden D, Kleinhenz ME, Golden JA, Sutter N, Tietje-Ulrich G, Criner RN, Arcasoy SM, Christie JD, Diamond J, Singer JP. Construct and Predictive Validity of Sarcopenia in Lung Transplant Candidates. Ann Am Thorac Soc. 2021 Sep; 18(9):1464-1474.  View on PubMed
  9. Anastasiou C, Trupin L, Glidden DV, Li J, Gianfrancesco M, Shiboski S, Schmajuk G, Yazdany J. Mortality Among Hospitalized Individuals With Systemic Lupus Erythematosus in the US Between 2006 and 2016. Arthritis Care Res (Hoboken). 2021 Oct; 73(10):1444-1450.  View on PubMed
  10. Spinelli MA, Glidden DV, Gennatas ED, Rutherford GW, Gandhi M. Effectiveness of Adding a Mask Recommendation to Other Public Health Measures. Ann Intern Med. 2021 08; 174(8):1193.  View on PubMed
  11. Mehrotra ML, Westreich D, Glymour MM, Geng E, Glidden DV. Transporting Subgroup Analyses of Randomized Controlled Trials for Planning Implementation of New Interventions. Am J Epidemiol. 2021 08 01; 190(8):1671-1680.  View on PubMed
  12. Bainbridge ED, Hsue PY, Esensten JH, Lynch KL, Hendrickson CM, Doernberg SB, Fung M, Chin-Hong P, Di Germanio C, Norris PJ, Simmons G, Glidden DV, Luetkemeyer AF. Characteristics of High-Titer Convalescent Plasma and Antibody Dynamics After Administration in Patients With Severe Coronavirus Disease 2019. Open Forum Infect Dis. 2021 Aug; 8(8):ofab385.  View on PubMed
  13. Eshun-Wilson I, Mody A, McKay V, Hlatshwayo M, Bradley C, Thompson V, Glidden DV, Geng EH. Public Preferences for Social Distancing Policy Measures to Mitigate the Spread of COVID-19 in Missouri. JAMA Netw Open. 2021 07 01; 4(7):e2116113.  View on PubMed
  14. Kuriakose S, Singh K, Pau AK, Daar E, Gandhi R, Tebas P, Evans L, Gulick RM, Lane HC, Masur H, NIH COVID-19 Treatment Guidelines Panel, Aberg JA, Adimora AA, Baker J, Kreuziger LB, Bedimo R, Belperio PS, Cantrill SV, Coopersmith CM, Davis SL, Dzierba AL, Gallagher JJ, Glidden DV, Grund B, Hardy EJ, Hinkson C, Hughes BL, Johnson S, Keller MJ, Kim AY, Lennox JL, Levy MM, Li JZ, Martin GS, Naggie S, Pavia AT, Seam N, Simpson SQ, Swindells S, Tien P, Waghmare AA, Wilson KC, Yazdany J, Zachariah P, Campbell DM, Harrison C, Burgess T, Francis J, Sheikh V, Uyeki TM, Walker R, Brooks JT, Ortiz LB, Davey RT, Doepel LK, Eisinger RW, Han A, Higgs ES, Nason MC, Crew P, Lerner AM, Lund C, Worthington C. Developing Treatment Guidelines During a Pandemic Health Crisis: Lessons Learned From COVID-19. Ann Intern Med. 2021 08; 174(8):1151-1158.  View on PubMed
  15. Ibrahim ME, Glidden DV, Grant RM, Anderson PL. Letter to the Editor: Revisiting the Pharmacological Forgiveness of HIV Pre-Exposure Prophylaxis. AIDS Res Hum Retroviruses. 2021 06; 37(6):407-408.  View on PubMed
  16. AlRasheed RM, Martin-Herz SP, Glidden DV, Okumura MJ. Adherence to Child Attention-Deficit/Hyperactivity Disorder Treatment Guidelines in Medical Homes-Results from a National Survey. J Dev Behav Pediatr. 2021 May 21.  View on PubMed
  17. Mody A, Tram KH, Glidden DV, Eshun-Wilson I, Sikombe K, Mehrotra M, Pry JM, Geng EH. Novel Longitudinal Methods for Assessing Retention in Care: a Synthetic Review. Curr HIV/AIDS Rep. 2021 08; 18(4):299-308.  View on PubMed
  18. Glidden DV, Das M, Dunn DT, Ebrahimi R, Zhao Y, Stirrup OT, Baeten JM, Anderson PL. Using the adherence-efficacy relationship of emtricitabine and tenofovir disoproxil fumarate to calculate background hiv incidence: a secondary analysis of a randomized, controlled trial. J Int AIDS Soc. 2021 05; 24(5):e25744.  View on PubMed
  19. Spinelli MA, Lynch KL, Yun C, Glidden DV, Peluso MJ, Henrich TJ, Gandhi M, Brown LB. SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus neutralising antibody titres after infection, compared by HIV status: a matched case-control observational study. Lancet HIV. 2021 06; 8(6):e334-e341.  View on PubMed
  20. Johnson KA, Niu X, Glidden DV, Castillo-Mancilla JR, Yager J, MaWhinney S, Morrow M, Okochi H, Cressey TR, Drain PK, Gandhi M, Anderson PL, Spinelli MA. Lower Urine Tenofovir Concentrations Among Individuals Taking Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate: Implications for Point-of-Care Testing. Open Forum Infect Dis. 2021 Jul; 8(7):ofab200.  View on PubMed

Go to UCSF Profiles, powered by CTSI